Endocan Levels and Endothelial Dysfunction in Patients With Sarcoidosis

Angiology - Tập 69 Số 10 - Trang 878-883 - 2018
Gönül Açıksarı1, Murat Kavas2, Adem Atıcı3, Şeref Kul1, Hayriye Erman4, Yusuf Yılmaz1, Kenan Demircioğlu1, Emre Yalçınkaya4, Asiye Kanbay5, Mustafa Çalışkan1
1Department of Cardiology, Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey
2Department of Pulmonary Diseases, University of Health Sciences, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey
3Department of Cardiology, Mus State Hospital, Mus, Turkey
4Department of Biochemistry, Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey
5Department of Pulmonary Diseases, Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey

Tóm tắt

A systemic inflammatory reaction is a common feature of both sarcoidosis and atherosclerosis. Endothelial-cell specific molecule 1 (endocan) is a marker of vascular pathology which also shows a correlation with inflammation, endothelial dysfunction, and atherosclerosis. The objective of this study was to evaluate the vascular involvement in sarcoidosis using serum endocan levels and brachial artery flow–mediated dilation (FMD), a marker of endothelial dysfunction. We included 53 patients with sarcoidosis without conventional cardiovascular risk factors and 40 healthy controls. Endothelial function was assessed using FMD. Endocan concentrations were measured using a commercially available enzyme-linked immunoassay. Patients with sarcoidosis had significantly higher endocan levels (306 [68] ng/mL vs 269 [73] ng/mL; P = .039) and lower FMD (2.7% [2.3%-3.2%] vs 8% [5%-13%]; P < .001) compared with the healthy group. A negative correlation was found between endocan levels and FMD in the sarcoidosis group ( r = −.325, P < .007). We conclude that sarcoidosis is associated with high levels of endocan and lower FMD values, which may indicate endothelial dysfunction and an early stage of atherosclerosis.

Từ khóa


Tài liệu tham khảo

10.1097/00002281-200101000-00014

10.1016/j.ijcard.2010.09.083

10.3109/08037051.2012.656397

Yildiz M, 2010, Open Cardiovasc Med J, 4, 83

10.1161/CIRCULATIONAHA.106.685206

10.1016/j.mvr.2015.03.008

10.1016/j.clinbiochem.2012.03.009

10.1016/j.ejvs.2005.11.001

10.2147/vhrm.2006.2.1.19

10.1007/5584_2015_205

10.1016/j.diii.2017.04.004

10.1016/j.bbcan.2005.08.004

10.4049/jimmunol.167.6.3099

10.1164/ajrccm.165.2.ats01

Hunninghake GW, 1999, Sarcoidosis Vasc Diffuse Lung Dis, 16, 149

10.1016/S0735-1097(01)01746-6

10.1016/S0735-1097(01)01657-6

10.1111/j.1445-5994.2007.01590.x

Menon P, 2011, Circulation, 124, A15455, 10.1161/circ.124.suppl_21.A17432

Von Feldt JM, 2008, Bull NYU Hosp Jt Dis, 66, 184

10.1055/s-2004-836148

10.1159/000117103

10.1002/art.22634

10.1111/1756-185x.12021

10.1016/j.ijcard.2011.06.112

10.1016/j.atherosclerosis.2017.05.005

10.1016/j.atherosclerosis.2015.09.030

10.1016/S0021-9150(03)00097-2

10.1111/bjd.12525

10.1038/ki.2014.227

10.1002/jcp.24485

10.1097/01.CCM.0000198525.82124.74

10.1177/0003319715568973

10.1177/0003319714548870

10.1177/0003319713513492

10.1177/1076029615618024

10.1016/j.jaad.2013.09.013

10.1177/0003319715616240

10.1177/1076029616639701

10.1097/MBC.0000000000000071

10.1515/cclm-2013-0638

10.1172/JCI114688

10.1056/NEJM199502233320801

10.3109/08037051.2014.972816

10.1074/jbc.271.34.20458

Thông tin
Thông tin xuất bản

Angiology

Tập 69 Số 10

878-883

Thông tin tác giả